Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 30-year-old male with alopecia areata who recovered after treatment with the homeopathic remedy Pix Liquida.

This study found that adding procapil to minoxidil was more effective than minoxidil alone in improving hair count, patient satisfaction, and dermatologist assessment scores for treating androgenetic alopecia over 12 months.

This study investigated the integration of crystal engineering and microneedle technology for androgenetic alopecia treatment, finding that microneedles loaded with newly developed Kopexil multicomponent crystals reduced drug diffusion rates in vitro compared to standard formulations.

This study found that the oral Janus kinase inhibitor CP-690,550 has a direct effect on reducing pruritus in patients with psoriasis, independent of clinician-assessed improvements in psoriasis severity.

In this study, Cyperus rotundus essential oil was found to have significantly better depigmenting effects than hydroquinone for treating axillary hyperpigmentation, with additional benefits in reducing inflammation and hair growth, making it a cost-effective and safe treatment option.

In this pilot study, baicalin-containing serum significantly decreased hair loss and increased hair growth after two months in participants with telogen effluvium, as subjective and objective assessments showed statistically significant improvements in hair thickness and density.

In this study on mice, a hydro-alcoholic solution containing kopexil significantly enhanced hair growth and increased hair-promoting factors without causing notable liver or kidney toxicity compared to minoxidil.

This study found that combining intralesional PTX and corticosteroids may enhance treatment outcomes for alopecia areata, with PTX showing better long-term effects compared to corticosteroids alone.

This case report describes a 30-year-old man with alopecia areata who experienced recovery following treatment with the homeopathic medication Pix Liquida.

This study developed a delivery platform using hyaluronic acid-based dissolvable microneedles with nanoliposomes containing kopexil and kopyrrol, which showed improved hair regeneration for treating androgenetic alopecia in vivo at lower dosages compared to minoxidil.

In this study, a novel liposomal peptide formulation significantly enhanced hair growth in mice compared to minoxidil, but results on human tissue penetration were inconclusive, suggesting further research is needed for translation to human use.

This randomized controlled trial found that topical 5% minoxidil was more effective than topical 5% Procapil in treating androgenetic alopecia after six months, as indicated by patient self-assessment, global photography, and researcher evaluation, with statistically significant differences favoring minoxidil.

In this study, topical phenylephrine significantly reduced hair shedding and increased the force needed to pluck hair in women undergoing cosmetic procedures, suggesting its potential utility for traction alopecia.

This study found that a specific amino-pyridine compound showed potent androgen receptor antagonist activity, stimulating hair growth in mice and reducing sebum production in a hamster model.

Cortexolone 17a-propionate may be an effective new treatment for hair loss.

This study found that a new formulation kit of Pielus Anti-hair loss lotion and shampoo, used daily for 90 days, was safe and effective in reducing hair loss and increasing hair strength and density among patients with telogen effluvium and/or androgenetic alopecia.

This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.

This study found no significant difference in anagen rate improvement between the CYP-based dietary supplement and placebo in women over 60 with telogen effluvium, possibly due to variable patient inclusion related to hair growth seasonality.

This study found that both intralesional pentoxifylline and intralesional corticosteroids improved hair regrowth in patients with localized alopecia areata, but intralesional corticosteroids were more effective, achieving 100% hair regrowth compared to 60% with pentoxifylline.

This study evaluated a new anti-baldness product, IPSTiC patch hair, designed to treat androgenetic alopecia, and reported that it effectively inhibits NO radical and 5α-reductase activity while maintaining safety and stability, suggesting its potential for topical use.

This study reports that a patient with rare linear lichen planopilaris experienced complete hair regrowth after 12 weeks of treatment with the antibody ixekizumab, suggesting it as a potential targeted therapy.

In this study, Caizhixuan hair tonic was found to promote hair growth in androgenetic alopecia mice by regulating the PI3K/Akt and apoptosis pathways.

This study reported that a new polymeric formulation for topical minoxidil delivery in an animal model improved hair growth and hair follicle formation more effectively than minoxidil in PBS, suggesting potential as a future hair loss treatment.

This study found that a new compounded topical solution for alopecia was clinically tolerable and did not cause irritation, while also showing potential to enhance hair growth through fibroblast proliferation and gene expression.

In this study, 1% pimekrolimus cream was found to be more effective than 0.05% clobetasol propionate for treating active plaques in patients with alopecia areata.

In this clinical trial, supplementation with Lambdapil® Anti Hair Loss capsules for 6 months significantly improved hair resistance and volume in women and increased the anagen/telogen hair ratio in men, indicating enhanced hair growth compared to the placebo group.

This study reports a case of complete hair regrowth in lichen planopilaris after 12 weeks of treatment with ixekizumab, suggesting its potential as a targeted therapy.

This study found that the HPCH-based formulation P-08–016 may facilitate finasteride deposition in the dermis, potentially offering an alternative to systemic therapy by minimizing systemic absorption.